**Benchmarks**

**A simple method to generate stable cell lines for the analysis of transient protein-protein interactions**

Emilia Elizabeth Savage, Denise Wootten, Arthur Christopoulos, Patrick Michael Sexton and Sebastian George Barton Furness

*Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia*


Keywords: BRET; flpIN; Gateway; protein interaction; bicistronic vector; arrestin; GPCR

Transient protein-protein interactions form the basis of signal transduction pathways in addition to many other biological processes. One tool for studying these interactions is bioluminescence resonance energy transfer (BRET). This technique has been widely applied to study signaling pathways, in particular those initiated by G protein-coupled receptors (GPCRs). These assays are routinely performed using transient transfection, a technique that has limitations in terms of assay cost and variability, overexpression of interacting proteins, vector uptake limited to cycling cells, and non-homogenous expression across cells within the assay. To address these issues, we developed bicistronic vectors for use with Life Technology’s Gateway and flpIN systems. These vectors provide a means to generate isogenic cell lines for comparison of interacting proteins. They have the advantage of stable, single copy, isogenic, homogeneous expression with low inter-assay variation. We demonstrate their utility by assessing ligand-induced interactions between GPCRs and arrestin proteins.

Bioluminescence Resonance Energy Transfer (BRET) is a popular method for monitoring transient protein-protein interactions in live cells. It has been widely applied to study interactions between G protein-coupled receptors (GPCRs) and their interacting proteins such as G proteins, arrestins, G protein-coupled receptor kinases (GRKs) and other GPCRs (1,2).

This assay relies on the fusion of genetically encoded *Renilla* luciferase (RLuc) donor and green fluorescent protein (GFP) acceptor proteins to the interacting partners. To monitor interactions, cDNA chimeras encoding interacting partners (fused with donor and acceptor) are routinely prepared in separate plasmids and transiently co-transfected prior to the assay. Transient transfection assays can exhibit wide inter-assay variation due to variable transfection efficiency and may be costly in high-throughput formats, depending on the transfection reagent used. Transient transfections also typically result in very high transgene expression, potentially leading to a high baseline BRET signal or a low signal-to-noise ratio in ligand-induced BRET due to a high level of non-specific (collisional) interactions. In addition, overexpression can significantly alter the pharmacological behavior of receptors. During transient transfection, only a subpopulation of cells are transfected and there is a significant cell-cycle bias for DNA uptake, which has the potential to skew results of interaction studies (3).

To overcome the limitations of transient transfection and establish a reliable method for isogenic expression of interacting proteins, we designed bicistronic BRET vectors that take advantage of Life Technologies’ Gateway cloning and flpIN cell line systems. These vectors are based on the pEF5/FRT/V5-DEST flpIN destination vector from Life Technologies. This vector yields stable incorporation into a single (isogenic) site in the genome of flpIN cell lines. The *EF1α* promoter that drives expression of the bicistronic transcript is mammalian, rather than viral in origin, and provides stable expression. The encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) was chosen as this has been demonstrated to harbour true IRES activity in mammalian cells (4). It was placed upstream of the acceptor cDNA fusion as it has been shown to drive 7 to 10-fold greater expression of the second cistron (5). Thus the acceptor fusion will be in excess compared to the donor, minimizing the bystander BRET effect (6). We call these vectors BIVISTI for BRET IRES vector for isogenic stable incorporation to monitor transient interaction.

The parental pEF5/FRT/V5-DEST vector contains a V5 epitope tag downstream of the second recombinant site and is flanked by BstBI and Pmel restriction sites. We designed an

**Method summary:**

Here we present a series of bicistronic vectors based on the Gateway and flpIN systems which enable the rapid generation of isogenic cell lines for protein-protein interaction assays. As proof of principle, we assess ligand-induced interactions between G protein-coupled receptors and arrestin proteins generated via isogenic cell lines.
insert flanked by BstB1 and Pme1 sites that would replace this sequence with one containing a cassette with the coding sequence for RLuc8 (GenBank: EF446136.1) followed by the unattenuated EMCV IRES sequence (nucleotides 149–713 relative to the polyprotein start site of GenBank: DQ288856) and a coding sequence for either ARRB1 (β-arrestin 1, GenBank: NM_004041.3) or ARRB2 (β-arrestin 2, GenBank: NM_004313.3) in frame with the GFP variant Venus (GenBank: DQ092360). The RLuc8 sequence was placed in reading frame B, relative to the Gateway cassette, yielding a 26 amino acid linker when used with a stop codon-deleted coding sequence from a Gateway entry vector. The bicistronic insert comprises the Renilla luciferase variant RLuc8 followed by the EMCV IRES sequence, β-arrestin 1 or 2 fused to the GFP variant Venus. Key vector features are indicated using standard contractions.

Figure 1. Scheme for replacement of the V5 epitope tag of parental vector pEF5/FRT/V5-DEST with the bicistronic BRET insert to generate a BIVISTI vector. 5' BstB1 and 3' Pme1 sites corresponding to those flanking the V5 epitope flank the bicistronic insert. The bicistronic insert comprises the Renilla luciferase variant RLuc8 followed by the EMCV IRES sequence, β-arrestin 1 or 2 fused to the GFP variant Venus. Key vector features are indicated using standard contractions.
Figure 2. Ligand-induced recruitment of ARRB2 & ARRB1 to AVPR2, GLP1R and CHRM1 receptors. (A), Stable flpIN CHO cell lines expressing AVPR2-RLuc8/ARRB2-Venus (green), CHRM1-RLuc8/ARRB2-Venus (orange), GLP1R-Rluc8/ARRB2-Venus (blue) or flpIN CHO cells transiently transfected with AVPR2/ARRB2-Venus (black) and stimulated with 1µM arginine vasopressin for AVPR2/ARRB2-Venus or 100nM GLP-1(7–36)NH2 for GLP1R-Rluc8/ARRB2-Venus. Data shown are mean ± SEM from 3–4 independent experiments performed in triplicate over passages 17 to 35. Peak ligand induced milliBRET responses for ARRB2 recruitment are 87 ± 3.2 (AVPR2), 16.2 ± 3.3 (CHRM1), 24 ± 2.1 (GLP1R), and 71 ± 4 (AVPR2 transient), respectively. (B) and (C) are the same as A but with expanded y-axis shown for CHRM1-RLuc8/ARRB2-Venus (B) and GLP1R-Rluc8/ARRB2-Venus (C). (D), concentration response curve for GLP-1(7–36)NH2 induced recruitment of ARRB2 in the stable flpIN CHO, GLP1R-Rluc8/ARRB2-Venus cell line. Data are fit to the three-parameter logistic equation. The $R^2$ for the curve fit is 0.92 with a calculated pEC$_{50}$ of 7.5 ± 0.1. Data are the mean ± SEM of four independent experiments conducted in triplicate. (E), comparison of concentration response curve for GLP-1(7–36)NH2 stimulated cAMP accumulation in GLP1R (black) and GLP1R-Rluc8/ARRB2-Venus (blue) flpIN CHO stable cell lines. Data are normalized to the maximum cellular response to forskolin (%FSK max) and fit to the three-parameter logistic equation. The pEC$_{50}$ values are 9.9 ± 0.1 and 10.2 ± 0.1. Data are the mean ± SEM of four independent experiments conducted in triplicate. (F), stable flpIN CHO cell lines expressing CHRM1-RLuc8/ARRB1-Venus (orange) or GLP1R-Rluc8/ARRB1-Venus (blue) were respectively stimulated with 100µM acetylcholine or 100nM GLP-1(7–36)NH2. Data shown are mean ± SEM from 3–4 independent experiments performed in triplicate over passages 17 to 35. No ligand induced ARRB1 recruitment is evident for CHRM1, whereas GLP1R showed a peak recruitment of are 24 ± 3 milliBRET in response to 100nM GLP-1(7–26)NH2.

Figure 3. Flow cytometric analysis of GLP1R and ARRB2-Venus expression in stable flpIN CHO cells. Untagged GLP1R (black) and cMycGLP1R-Rluc8/ARRB1-Venus (blue) flpIN CHO cells were stained with AF647–9E10 and Sytox blue and live cells analyzed for Venus and cMycGLP1R expression [(A), (B) and (C)]. (A) and (B) are histograms of relative fluorescence intensity of Venus and AF647–9E10, respectively, with the density plot in (C) showing relative fluorescence intensity of Venus plotted against that of AF647–9E10. (D) is a histogram of the relative fluorescence intensity of Venus from the CHRM1/ARRB2 flpIN CHO cell line at passage 17 (light orange) and 35 (dark orange) with stained, untagged GLP1R flpIN CHO as the control (black). (E) is a histogram of the relative fluorescence intensity of Venus from the GLP1R/ARRB2 flpIN CHO cell line at passage 17 (light blue) and 35 (dark blue) with stained, untagged GLP1R flpIN CHO as the control (black). (F) is a histogram of the relative fluorescence intensity of Venus from the AVPR2/ARRB2 (green), CHRM1/ARRB2 (orange) and GLP1R/ARRB2 (blue) flpIN CHO cell lines with stained, untagged GLP1R flpIN CHO as the control (black).
in parallel. Figure 3 shows the distribution of expression as a histogram plot for direct fluorescence from the Venus-tagged ARRB2 (Figure 3A, blue) and cMyc-tagged GLP1R-RLuc8 (Figure 3B, blue). The direct correlation of ARRB2 and GLP1R expression is demonstrated in the contour plot in Figure 3C (blue). The stability of expression over time was assessed by analysis of Venus fluorescence of the CHRM1/ARRB2 and GLP1R/ARRB2 cell lines at passage 17 and 35 (Figure 3D, orange and E, blue). A comparison of ARRB2-Venus expression between AVPR2/ARRB2 (green), CHRM1/ARRB2 (orange), and GLP1R/ARRB2 (blue) cell lines was also performed with stained untagged GLP1R cells as a control (black) (Figure 3F).

In conclusion, we report a simplified scheme for generation of stable cell lines expressing both donor and acceptor fusion partners for protein-protein interaction studies by BRET. The incorporation of Gateway technology for the donor fusion makes this a useful tool for the development of cell lines for screening GPCR-protein interactions by BRET. The incorporation of Gateway technology for the donor fusion makes this a useful tool for the development of cell lines for screening GPCR-protein interactions by BRET. The incorporation of Gateway technology for the donor fusion makes this a useful tool for the development of cell lines for screening GPCR-protein interactions by BRET.

Acknowledgements

PMS and AC are Principal Research Fellows of the National Health and Medical Research Council of Australia (NHMRC). This work was funded by the NHMRC program grant #519461.

Competing interests

The authors declare no competing interests.

References